State Street SPDR S&P Biotech ETF (XBI) Latest News, Market Updates & Sentiment | Edgen
Back
Home
Stock
XBI
State Street SPDR S&P Biotech ETF (XBI)
XBI Stock Price Chart
XBI
State Street SPDR S&P Biotech ETF
$159.1
-3.15%
$-5.18
As of today:Jul 10, 15:04:47 GMT-4
Overview
Forecast
Holdings
News
Article
Key Stats
Prev.Close
$164.28
Open
$164.19
Day's Range
$156.27 - $164.19
52 week range
$80.9 - $159.1
Volume
9.8M
Avg.Volume
9.1M
Dividend yield
0.37%
Net Assets
$0
NAV
--
Expense Ratio
--
Shares Outstanding
68.4M
What is XBI?
XBI was created on 2006-01-31 by SPDR. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 8347.79m in AUM and 144 holdings. XBI tracks an equal-weighted index of US biotechnology stocks.
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Crypto Comparison
Home Page
Markets
US Stocks
HK Stocks
Crypto
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
Terms of Use
Privacy Policy
Sitemap
© 2026 Edgen Powered by
Moderna drops 11%, ImmunityBio and Sarepta slide 8% in biotech rout
Jul 10 2026, 16:38
Nasdaq Biotechnology Index slides 3% as gene therapy stocks lead selloff
Jul 10 2026, 14:59
Protagonist Therapeutics rallies 64% on rusfertide FDA path and Icotyde royalties
Jul 07 2026, 16:43
Erasca faces class action as ERAS-0015 data triggers 54% stock collapse
Jul 06 2026, 14:34
Moderna jumps 9.2% as pipeline progress and flu data fuel rally
Jul 02 2026, 20:05
Kymera surges 51% YTD as oral STAT6 degrader accelerates toward pivotal data
Jul 01 2026, 18:40
Erasca loses $2.8 billion after patient death, patent infringement suit
Jun 30 2026, 23:27
Moderna jumps 12% to 52-week high on mRNA expansion beyond vaccines
Jun 29 2026, 18:24
Moderna surges to lead S&P 500 after unveiling cell therapy program
Jun 26 2026, 15:57
Erasca faces class action after 54% stock collapse on patent, safety issues
Jun 25 2026, 00:54
Viking Therapeutics emerges as dark-horse threat to $36.5B obesity drug market
Jun 23 2026, 00:53
Praxis Precision Medicines gains 4% on FDA breakthrough therapy for elsunersen
Jun 22 2026, 18:05
Moderna flu shot wins unanimous FDA panel vote ahead of August decision
Jun 19 2026, 13:38
Mirum, Incyte's zilurgisertib cuts FOP lesions 81% as FDA starts Priority Review
Jun 16 2026, 09:30
Erasca loses $2.8B in market cap as class action targets patent, safety issues
Jun 16 2026, 01:28
Praxis Precision Medicines drops 12% as epilepsy drug fails main trial goal
Jun 01 2026, 22:34
Gilead's $2.4B cash flow questions Moderna's 63% stock surge
May 21 2026, 14:04
Erasca stock plunges 48% after patent infringement allegations
May 19 2026, 23:25